The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial
Open accessAbstract
IMPORTANCE: Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI) are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early colon cancer. However, the effect of MMRD and MSI in curatively resected gastric cancer treated with perioperative chemotherapy is unknown. OBJECTIVE: To examine the association among MMRD, MSI, and survival in patients with resectable gastroesophageal cancer randomized to surgery alone or perioperative epirubicin, cisplatin, and fluorouracil chemotherapy in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. DESIGN, SETTING, AND PARTICIPANTS: This secondary post hoc analysis of the MAGIC trial included participants who were treated with surgery alone or perioperative chemotherapy plus surgery for operable gastroesophageal cancer from July 1, 1994, through April 30, 2002. Tumor sections were assessed for expression of the MMR proteins mutL homologue 1, mutS homologue 2, mutS homologue 6, and PMS1 homologue 2. The association among MSI, MMRD, and survival was assessed. MAIN OUTCOMES AND MEASURES: Interaction between MMRD and MSI status and overall survival (OS). RESULTS: Of the 503 study participants, MSI results were available for 303 patients (283 with microsatellite stability or low MSI [median age, 62 years; 219 males (77.4%)] and 20 with high MSI [median age, 66 years; 14 males (70.0%)]). A total of 254 patients had MSI and MMR results available. Patients treated with surgery alone who had high MSI or MMRD had a median OS that was not reached (95% CI, 11.5 months to not reached) compared with a median OS among those who had neither high MSI nor MMRD of 20.5 months (95% CI, 16.7-27.8 months; hazard ratio, 0.42; 95% CI, 0.15-1.15; P = .09). In contrast, patients treated with chemotherapy plus surgery who had either high MSI or MMRD had a median OS of 9.6 months (95% CI, 0.1-22.5 months) compared with a median OS among those who were neither high MSI nor MMRD of 19.5 months (95% CI, 15.4-35.2 months; hazard ratio, 2.18; 95% CI, 1.08-4.42; P = .03). CONCLUSIONS AND RELEVANCE: In the MAGIC trial, MMRD and high MSI were associated with a positive prognostic effect in patients treated with surgery alone and a differentially negative prognostic effect in patients treated with chemotherapy. If independently validated, MSI or MMRD determined by preoperative biopsies could be used to select patients for perioperative chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Self-citationRibic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Ychou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.-M., Saint-Aubert, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0597 · Cited by 2,086
Mandard, A.-M., Dalibard, F., Mandard, J.-C., Marnay, J., Henry-Amar, M., Petiot, J.-F., Roussel, A., Jacob, J.-H., Segol, P., Samama, G., et al. (1994) · Cancer · doi:10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c · Cited by 2,044
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623 · cited 2×
“In colorectal cancer, theputativeprognostic effectofMMR protein statuson thebenefit of adjuvant chemotherapy is limited to patients with stage II disease.(5) This finding is hypothesized to be attributable to the relatively small benefit associatedwithadjuvant fluoropyrimidine therapy inpatientswith stage II colorecta…”
Background(2006) · Cancer · doi:10.1002/(issn)1097-0142 · Cited by 1,470
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063 · cited 1×
“Tumorswereclassifiedasmicrosatellite stable (MSS)when allmarkerswere stable, as having lowMSI (MSI-L) when only 1marker was unstable, and asMSI-Hwithminimum instability in 2markers.(12)The term instability in this context refers to the presence of an increased number of nucleotide repeats in tumor than in thenontumor…”
BackgroundThe role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., & Boothman, D. A. (2001) · PubMed · Cited by 269
An, J. Y., Kim, H., Cheong, J., Hyung, W. J., Kim, H., & Noh, S. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.26399 · Cited by 161
Beghelli, S., Manzoni, G. D., Barbi, S., Tomezzoli, A., Roviello, F., Gregorio, C. D., Vindigni, C., Bortesi, L., Parisi, A., Saragoni, L., et al. (2006) · Surgery · doi:10.1016/j.surg.2005.08.021 · Cited by 148
Choi, Y. Y., Bae, J. M., An, J. Y., Kwon, I. G., Cho, I., Shin, H. B., Eiji, T., Aburahmah, M., Kim, H., Cheong, J., et al. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23618 · Cited by 143
Kim, S. Y., Choi, Y. Y., An, J. Y., Shin, H. B., Jo, A., Choi, H., Seo, S. H., Bang, H., Cheong, J., Hyung, W. J., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29449 · Cited by 128
Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer
Marrelli, D., Połom, K., Pascale, V., Vindigni, C., Piagnerelli, R., Franco, L. D., Ferrara, F., Roviello, G., Garosi, L., Petrioli, R., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4931-3 · Cited by 128
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer
Ivanova, T., Zouridis, H., Wu, Y., Cheng, L. L., Tan, I. B., Gopalakrishnan, V., Ooi, C.-H., Lee, J., Qin, L., Wu, J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301113 · Cited by 114
Chiaravalli, A. M., Feltri, M., Bertolini, V., Bagnoli, E., Furlan, D., Cerutti, R., Novario, R., & Capella, C. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-0066-4 · Cited by 92
A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine
Hansen, M. F., Johansen, J. A., Bjørnevoll, I., Sylvander, A. E., Steinsbekk, K. S., Sætrom, P., Sandvik, A. K., Drabløs, F., & Sjursen, W. (2015) · Familial Cancer · doi:10.1007/s10689-015-9803-2 · Cited by 84
Fang, W., Chang, S., Lan, Y., Huang, K., Chen, J., Lo, S.-S., Hsieh, M., Li, A. F., Wu, C.-W., & Chiou, S. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1652-7 · Cited by 76
Predictive value of CHFR and MLH1 methylation in human gastric cancer
Li, Y., Yang, Y., Lu, Y., Herman, J. G., Brock, M. V., Zhao, P., & Guo, M. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0370-2 · Cited by 75
Interobserver variability in the evaluation of mismatch repair protein immunostaining
Klarskov, L. L., Ladelund, S., Holck, S., Rønlund, K., Lindebjerg, J., Elebro, J., Halvarsson, B., von Salomé, J., Bernstein, I., & Nilbert, M. C. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.03.003 · Cited by 61
Cited by
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Self-citationCurrent treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
Wang, F., Shen, L., Li, J., Zhou, Z., Liang, H., Zhang, X., Tang, L., Xin, Y., Jin, J., Zhang, Y., et al. (2019) · Cancer Communications · doi:10.1186/s40880-019-0349-9 · Cited by 810
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Microsatellite instability: a review of what the oncologist should know
Li, K., Luo, H., Huang, L., Luo, H., & Zhu, X. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1091-8 · Cited by 509
Metadata
- Authors
- Smyth, E. C., Wotherspoon, A., Peckitt, C., Gonzalez, D., Hulkki-Wilson, S., Eltahir, Z., Fassan, M., Rugge, M., Valeri, N., Okines, A., Hewish, M., Allum, W., Stenning, S., Nankivell, M., Langley, R., & Cunningham, D.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 1197
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2592337042
- Cited by
- 521
- References
- 25
- FWCI
- 33.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.